Intriguingly, bromocriptine-induced activation of dopamine D2 receptors suppresses TGF-α mRNA expression prior to tumor shrinkage, suggesting its therapeutic promise for glioma (44). This evidence concerns the gene TGFA and central nervous system cancer.